Latest News Feed

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
Press Release Aug 6, 2026
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
Press Release Aug 3, 2026
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press Release Jul 21, 2026
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
Press Release Jul 10, 2026
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
Press Release Jun 1, 2026
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
Press Release May 11, 2026
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
Press Release May 7, 2026
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
Press Release Apr 6, 2026
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
Press Release Mar 30, 2026
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

- A majority of CKD patients present with cellular inflammation and immunoparalysis predose -

-Gemini durably normalizes cellular inflammation and restores immunocompetence -
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Press Release Mar 24, 2026
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Press Release Mar 19, 2026
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
Press Release Feb 26, 2026
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
Press Release Jan 26, 2026
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
Press Release Jan 23, 2026
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
Press Release Jan 21, 2026
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI

- Single Phase 2/3 Adaptive Study Design -

- Clinically Relevant, Objective Composite Endpoint -
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)
Press Release Jan 14, 2026
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)

- Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study -
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Press Release Jan 12, 2026
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development
Press Release Jan 7, 2026
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
Press Release Dec 1, 2025
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
Press Release Nov 20, 2025
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
Press Release Nov 6, 2025
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
Press Release Oct 29, 2025
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025
Press Release Oct 15, 2025
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
Press Release Sep 11, 2025
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
Press Release Sep 10, 2025
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients -

- Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease -

Data discussion webcast/conference call will be held at 8:30 am Eastern Time
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Press Release Sep 9, 2025
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study
Press Release Sep 9, 2025
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients -

- Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease -

Data discussion webcast/conference call will be held on Wednesday, September 10th at 8:30 am Eastern Time